American Society of Clinical Oncology

SHERPA: White

People

  1. Bajorin
    Bajorin
  2. Rosenberg
    Rosenberg
  3. Bosl
    Bosl
  4. Iyer
    Iyer
  5. Motzer
    Motzer
  6. Funt
    Funt
  7. Al-Ahmadie
    Al-Ahmadie
  8. Regazzi
    Regazzi
  9. Ostrovnaya
    Ostrovnaya
  10. Bochner
    Bochner

Groups

  1. Department of Medicine (280)
  2. Genitourinary Oncology Service (280)
  3. Solid Tumor Oncology Division (280)
  4. Surgery (121)
  5. Urology (119)
  6. Survivorship Research (112)
  7. Epidemiology and Biostatistics (82)
  8. Biostatistics Service (79)
  9. Department of Pathology and Laboratory Medicine (79)
  10. Hematology-Oncology Fellows (62)
Search Within
  1. "Dean Bajorin"
Formats
  1. Meeting Abstract (182)
  2. Journal Article (98)
Groups
  1. Department of Medicine (280)
  2. Genitourinary Oncology Service (280)
  3. Solid Tumor Oncology Division (280)
  4. Surgery (121)
  5. Urology (119)
  6. Survivorship Research (112)

More Groups

People
  1. Dean Bajorin (280)
  2. Jonathan Rosenberg (87)
  3. George Bosl (75)
  4. Gopakumar Iyer (69)
  5. Robert Motzer (65)
  6. Samuel Funt (60)

More People

Years
  1. 2025 (6)
  2. 2024 (8)
  3. 2023 (9)
  4. 2022 (13)
  5. 2021 (11)
  6. 2020 (17)

More Years

Publications
  1. Journal of Clinical Oncology (270)
  2. Journal of Oncology Practice (7)
  3. JCO Precision Oncology (3)

Results (280)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cutaneous toxicity and clinical outcomes with enfortumab vedotin and pembrolizumab in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Arbuiso, A.; Sternschuss, M.; Whiting, K.; Gupta, A.; Huttenlocher Bent, E.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Treatment patterns and clinical outcomes with platinum-based chemotherapy after enfortumab vedotin and pembrolizumab in patients with metastatic urothelial carcinoma
    Meeting Abstract

    Sternschuss, M.; Whiting, K.; Arbuiso, A.; Gupta, A.; Bent, E. H.; Alvarez, N.; Regazzi, A. M.; Liang, S.; Ahmed, F.; Akin, O.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adjuvant nivolumab (NIVO) vs placebo (PBO) for high-risk muscle-invasive urothelial carcinoma (MIUC): Additional efficacy outcomes including overall survival (OS) in patients (pts) with muscle-invasive bladder cancer (MIBC) from CheckMate 274
    Meeting Abstract

    Milowsky, M. I.; Galsky, M. D.; Witjes, J. A.; Gschwend, J. E.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Characterizing the immune effects of enfortumab vedotin (EV) on peripheral blood mononuclear cells (PBMCs) in metastatic urothelial cancer patients (mUC)
    Meeting Abstract

    Gupta, A.; Sevilla, C.; Pihlstrom, N. L.; Liang, S.; Regazzi, A. M.; McCoy, A. S.; Maher, C. A.; Wong, P.; Ahmed, F.; Funt, S. A.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Updated long-term follow-up from a phase II clinical trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for patients with high-grade upper tract urothelial carcinoma
    Meeting Abstract

    Jayalath, V.; Teo, M. Y.; Assel, M.; Rodriguez, D.; Meyerson, A.; Bochner, B. H.; Dalbagni, G.; Donat, S. M.; Herr, H. W.; Cha, E. K.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: Expanded efficacy from CheckMate 274
    Journal Article

    Galsky, M. D.; Witjes, J. A.; Gschwend, J. E.; Milowsky, M. I.; Schenker, M.; Valderrama, B. P.; Tomita, Y.; Bamias, A.; Lebret, T.; Shariat, S. F.; more...
    Journal of Clinical Oncology (2025)

    Fulltext@MSK | Save
  • HER2 and PD-L1 immunohistochemistry (IHC) expression, and HER2 genomic alterations: Associations and clinical outcomes for advanced bladder cancer
    Meeting Abstract

    Aggen, D. H.; Shah, N. J.; Zheng, J.; Alam, S. M.; Balar, O.; Niederhausern, A.; Regazzi, A. M.; Ratna, N.; Funt, S. A.; Teo, M. Y.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • HER2 mutation and bladder cancer (BC): Prevalence and clinical outcomes
    Meeting Abstract

    Shah, N. J.; Aggen, D. H.; Zheng, J.; Niederhausern, A.; Alam, S. M.; Balar, O.; Bahadur, N.; Watson, A.; Regazzi, A. M.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Neoadjuvant nivolumab (N) + ipilimumab (I) in cisplatin-ineligible patients with upper tract urothelial cancer (UTUC): Updated results
    Meeting Abstract

    Sternschuss, M.; Guercio, B. J.; Pietzak, E. J.; Ponomarev, M.; Regazzi, A. M.; Quinlan, C.; Aggen, D. H.; Goh, A. C.; Cha, E. K.; Donat, S. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Defining molecular features associated with microsatellite instability and response to immune checkpoint blockade in urothelial carcinoma
    Meeting Abstract

    Alam, S. M.; Teo, M. Y.; Woo, J.; Sarfaty, M.; Funt, S. A.; Aggen, D. H.; Lee, C. H.; Carlo, M. I.; Gandhi, J.; Ratna, N.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save